- Home
- TLNC vs ABEO Comparison
TLNC vs ABEO Comparison
Compare TLNC & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$5.01
Company Overview
Basic Information| Metric | TLNC | ABEO |
|---|---|---|
| Founded | 2025 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 345.2M | 280.2M |
| IPO Year | 2025 | 1980 |
Fundamental Metrics
Financial Performance| Metric | TLNC | ABEO |
|---|---|---|
| Price | $10.16 | $5.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $18.20 |
| AVG Volume (30 Days) | 93.7K | ★ 1.2M |
| Earning Date | 01-01-0001 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.29 |
| Revenue | N/A | ★ $400,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,589.77 |
| P/E Ratio | ★ N/A | $3.89 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.87 | $3.93 |
| 52 Week High | $10.18 | $7.54 |
Technical Indicators
Market Signals| Indicator | TLNC | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 57.83 | 46.16 |
| Support Level | $10.10 | $4.94 |
| Resistance Level | $10.16 | $5.26 |
| Average True Range (ATR) | 0.01 | 0.23 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 100.00 | 35.43 |
Price Performance
Historical Comparison TLNC
ABEO
About TLNC Talon Capital Corp. Class A Ordinary Shares
Talon Capital Corp is a newly organized blank check company.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.